

IDS Form PTO/SB/08: Substitute for form 1449A/PTO				Complete if Known:	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				<i>Application Number</i>	10/582,014
				<i>Filing Date</i>	June 7, 2006
				<i>First Named Inventor</i>	Takeshi Kuroda et al.
				<i>Art Unit</i>	To be Assigned
				<i>Examiner Name</i>	To be Assigned
Sheet 1 of 1	1	of	2	<i>Attorney Docket Number</i>	

U.S. PATENTS AND PUBLISHED U.S. PATENT APPLICATIONS

Note: Submission of copies of U.S. Patents and published U.S. Patent Applications is not required.

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Translation ⁶
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)				
		WO 2004/064860 A1	08-05-2004	Cincinnati Children's Hospital Medical Center		
		WO 2004/028535 A1	04-08-2004	Pintex Pharmaceuticals, Inc.		

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation ⁶
		PIA AZARSCHAB ET AL., "Aspirin promotes TFF2 gene activation in human gastric cancer cell lines," <i>FEBS Letters</i> , (2001), Vol. 488, No. 3, pp. 206-210	
		A. KOITABASHI ET AL., "Indometacin up-regulates TFF2 expression in gastric epithelial cells," (July 2004), Vol. 20, Suppl. 1, PP. 171-176	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
1187043 1

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /MS/

IDS Form PTO/SB/08: Substitute for form 1449A/PTO

CORRECTED**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Q1P/E
JUL 22 2009

Sheet

1

of

2

Attorney Docket Number

Complete if Known

Application Number	10/582,014
Filing Date	June 7, 2006
First Named Inventor	Takeshi Kuroda et al.
Art Unit	To be Assigned
Examiner Name	To be Assigned
Attorney Docket Number	4676-237

U.S. PATENTS AND PUBLISHED U.S. PATENT APPLICATIONS

Examiner Initials	Cite No. ¹	Document Number	Issue or Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
		US-			
		US-			

Note: Submission of copies of U.S. Patents and published U.S. Patent Applications is not required.

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Translation ⁶
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)				
		WO 92/14837 A1	09-03-92	The General Hospital Corporation		
		WO 02/102403 A1	12-27-02	Novo Nordisk A/S		
		WO 02/46226 A2	06-13-02	Novo Nordisk A/S		
		WO 01/02377 A1	01-11-01	Geron Corporation; Kyowa Hakko Kogyo Co., Ltd.		
		WO 02/051409 A1	07-04-02	Geron Corporation; Kyowa Hakko Kogyo Co., Ltd.		

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation ⁶
		DOUGLAS TAUPIN ET AL., "Trefoil Factors: Initiators of Mucosal Healing," <i>Nature Reviews/Molecular Cell Biology</i> , (2003), Vol. 4, pp. 721-732	
		RAYMOND J. PLAYFORD ET AL., "Human Spasmolytic Polypeptide Is a Cytoprotective Agent That Stimulates Cell Migration," <i>Gastroenterology</i> , (1995), Vol. 108, pp. 108-116	
		MARK W. BABYATSKY ET AL., "Oral Trefoil Peptides Protect Against Ethanol- and Indomethacin-Induced Gastric Injury in Rats," <i>Gastroenterology</i> , (1996), Vol. 110, pp. 489-497	
		C. MCKENZIE ET AL., "Topical and intravenous administration of trefoil factors protect the gastric mucosa from ethanol-induced injury in the rat," <i>Alim. Pharmacol. Ther.</i> , (2000), Vol. 14, pp. 1033-1040	
		S. S. POULSEN ET AL., "Metabolism of oral trefoil factor 2 (TFF2) and the effect of oral and parenteral TFF2 on gastric and duodenal ulcer healing in the rat," <i>Gut</i> , (1999), Vol. 45, pp. 516-522	
		C. P. TRAN ET AL., "Trefoil peptide TFF2 (spasmolytic polypeptide) potently accelerates healing and reduces inflammation in a rat model of colitis," <i>Gut</i> , (1999), Vol. 44, pp. 636-642	
		ANTONIO SORIANO-IZQUIERDO ET AL., "Trefoil peptide TFF2 treatment reduces VCAM-1 expression and leukocyte recruitment in experimental intestinal inflammation," <i>J. Leukoc. Biol.</i> , (2004), Vol. 75, pp. 214-223	
		JAMES J. FARRELL, "TFFS/SP-deficient mice show decreased gastric proliferation, increased acid secretion, and increased susceptibility to NSAID injury," <i>J. Clin. Invest.</i> , (2002), Vol. 109, pp. 193-204	
		L. THIM ET AL., "Effect of trefoil factors on the viscoelastic properties of mucus gels," <i>Eur. J. Clin. Invest.</i> , (2002), Vol. 32, pp. 519-527	
		NIKOLAOS M. NIKOLAIDIS ET AL., "Trefoil factor-2 Is an Allergen-Induced Gene Regulated by Th2 Cytokines and STAT6 in the Lung," <i>Am. J. Respir. Cell Mol. Biol.</i> , (2003), Vol. 29, pp. 458-464	
		P.L. BECK ET AL., "Chemotherapy- and Radiotherapy-Induced Intestinal Damage Is Regulated by Intestinal Trefoil Factor," <i>Gastroenterology</i> , (2004), Vol. 126, pp. 796-808	
		OLIVIER LEFEBVRE ET AL., "Gastric Mucosa Abnormalities and Tumorigenesis in Mice Lacking the pS2 Trefoil Protein," <i>Science</i> , (1996), Vol. 274, pp. 259-262	
		WON SANG PARK ET AL., "Somatic Mutations of the Trefoil Factor Family 1 Gene in Gastric Cancer," <i>Gastroenterology</i> , (2000), Vol. 119, pp. 691-698	
		MASARU KATOH, "Trefoil factors and human gastric cancer (Review)," <i>Int. J. Mol. Med.</i> , (2003), Vol. 12, pp. 3-9	

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /MS/

IDS Form PTO/SB/08: Substitute for form 1449A/PTO				<i>Complete if Known</i>	
CORRECTED INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	10/582,014
Sheet	2	of	2	Filing Date	June 7, 2006
				First Named Inventor	Takeshi Kuroda et al.
				Art Unit	To be Assigned
				Examiner Name	To be Assigned
				Attorney Docket Number	4676-237

NON PATENT LITERATURE DOCUMENTS					
		T. SHIMADA ET AL., "Up-regulation of TFF expression by PPAR γ ligands in gastric epithelial cells," <i>Alim. Pharmacol. Ther.</i> , (2003), Vol. 18 (suppl. 1), pp. 119-125			
		TADAHITO SHIMADA, "PPAR γ mediates NSAIDs-induced upregulation of TFF2 expression in gastric epithelial cells," <i>FEBS Lett.</i> , (2004), Vol. 558, pp. 33-38			
		TAKUJI TANAKA ET AL., "Ligands for Peroxisome Proliferator-activated Receptors α and γ Inhibit Chemically Induced Colitis and Formation of Aberrant Crypt Foci in Rats ¹ ," <i>Can. Res.</i> , (2001), Vol. 61, pp. 2424-2428			
		CONCEPCIÓN FERNÁNDEZ-ESTÍVARIZ, "Trefoil peptide expression and goblet cell number in rat intestine: effects of KGF and fasting-refeeding," <i>Am. J. Physiol. Regul. Integr. Comp. Physiol.</i> , (2003), Vol. 84, pp. R564-R573			

Examiner Signature	/D Margaret Seaman/	Date Considered	07/31/2009
--------------------	---------------------	-----------------	------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1187131_1

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /MS/